Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding the medication dapagliflozin to existing treatments (liraglutide and insulin) helps lower blood sugar levels in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 26 people

Who can join Ages 18–80 · all sexes

Timeline Started 2015-08 · est. completion 2016-04

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02518945 ↗

Description as written by the study sponsor.

This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.

Treatments tested

Dapagliflozin also known as Farxiga Drug

Dapagliflozin or Farxiga is a SGLT-2 inhibitor
Insulin also known as Lantus, Levemir, Toujjeo, Humalog , Novolog, Apidra Drug
Liraglutide also known as Victoza Drug

Victoza(Liraglutide) is a GLP-1 agent.
Dapagliflozin placebo also known as Placebo Drug

Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin

Main thing measured	Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.
Sponsor	University at Buffalo
Conditions studied	Type 1 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02518945 ↗